Logo image of ALDVI.PA

ADVICENNE (ALDVI.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ALDVI - FR0013296746 - Common Stock

1.692 EUR
-0.08 (-4.51%)
Last: 1/16/2026, 7:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ALDVI. ALDVI was compared to 53 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ALDVI have multiple concerns. ALDVI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ALDVI has reported negative net income.
  • ALDVI had negative earnings in each of the past 5 years.
  • ALDVI had a negative operating cash flow in each of the past 5 years.
ALDVI.PA Yearly Net Income VS EBIT VS OCF VS FCFALDVI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

1.2 Ratios

  • ALDVI's Return On Assets of -96.03% is on the low side compared to the rest of the industry. ALDVI is outperformed by 86.79% of its industry peers.
Industry RankSector Rank
ROA -96.03%
ROE N/A
ROIC N/A
ROA(3y)-69.72%
ROA(5y)-67.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALDVI.PA Yearly ROA, ROE, ROICALDVI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

  • ALDVI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALDVI.PA Yearly Profit, Operating, Gross MarginsALDVI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

  • ALDVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ALDVI remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for ALDVI has been increased compared to 5 years ago.
  • ALDVI has a worse debt/assets ratio than last year.
ALDVI.PA Yearly Shares OutstandingALDVI.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ALDVI.PA Yearly Total Debt VS Total AssetsALDVI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -12.31, we must say that ALDVI is in the distress zone and has some risk of bankruptcy.
  • ALDVI has a Altman-Z score of -12.31. This is amonst the worse of the industry: ALDVI underperforms 81.13% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.31
ROIC/WACCN/A
WACC7.36%
ALDVI.PA Yearly LT Debt VS Equity VS FCFALDVI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • ALDVI has a Current Ratio of 0.59. This is a bad value and indicates that ALDVI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.59, ALDVI is doing worse than 88.68% of the companies in the same industry.
  • A Quick Ratio of 0.45 indicates that ALDVI may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.45, ALDVI is doing worse than 83.02% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.59
Quick Ratio 0.45
ALDVI.PA Yearly Current Assets VS Current LiabilitesALDVI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

6

3. Growth

3.1 Past

  • ALDVI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.14%, which is quite good.
  • Looking at the last year, ALDVI shows a small growth in Revenue. The Revenue has grown by 4.75% in the last year.
  • ALDVI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.63% yearly.
EPS 1Y (TTM)14.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.3%
Revenue 1Y (TTM)4.75%
Revenue growth 3Y-0.46%
Revenue growth 5Y9.63%
Sales Q2Q%67.79%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.63% on average over the next years. This is a very strong growth
  • ALDVI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.89% yearly.
EPS Next Y17.08%
EPS Next 2Y27.95%
EPS Next 3Y25.63%
EPS Next 5YN/A
Revenue Next Year54.05%
Revenue Next 2Y39.5%
Revenue Next 3Y37.89%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALDVI.PA Yearly Revenue VS EstimatesALDVI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M
ALDVI.PA Yearly EPS VS EstimatesALDVI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALDVI. In the last year negative earnings were reported.
  • Also next year ALDVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALDVI.PA Price Earnings VS Forward Price EarningsALDVI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALDVI.PA Per share dataALDVI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

  • ALDVI's earnings are expected to grow with 25.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.95%
EPS Next 3Y25.63%

More info and screens

0

5. Dividend

5.1 Amount

  • ALDVI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ADVICENNE

EPA:ALDVI (1/16/2026, 7:00:00 PM)

1.692

-0.08 (-4.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-25
Earnings (Next)03-25
Inst Owners18.24%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap24.06M
Revenue(TTM)2.63M
Net Income(TTM)-6.46M
Analysts84.44
Price Target4.08 (141.13%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.14
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.53
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.19
BVpS-1.69
TBVpS-1.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -96.03%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.72%
ROA(5y)-67.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.59
Quick Ratio 0.45
Altman-Z -12.31
F-ScoreN/A
WACC7.36%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.3%
EPS Next Y17.08%
EPS Next 2Y27.95%
EPS Next 3Y25.63%
EPS Next 5YN/A
Revenue 1Y (TTM)4.75%
Revenue growth 3Y-0.46%
Revenue growth 5Y9.63%
Sales Q2Q%67.79%
Revenue Next Year54.05%
Revenue Next 2Y39.5%
Revenue Next 3Y37.89%
Revenue Next 5YN/A
EBIT growth 1Y-34.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.91%
EBIT Next 3Y31.15%
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

ADVICENNE / ALDVI.PA FAQ

What is the ChartMill fundamental rating of ADVICENNE (ALDVI.PA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALDVI.PA.


Can you provide the valuation status for ADVICENNE?

ChartMill assigns a valuation rating of 1 / 10 to ADVICENNE (ALDVI.PA). This can be considered as Overvalued.


How profitable is ADVICENNE (ALDVI.PA) stock?

ADVICENNE (ALDVI.PA) has a profitability rating of 0 / 10.